Just like a detective trying to solve a complex case, scientists have been tirelessly investigating the puzzle of Parkinson’s disease (PD). PD, the second most common neurodegenerative disease, presents with distinct motor symptoms. With millions of patients affected globally, understanding the underlying causes and finding potential treatments is crucial. Among the many factors involved in PD, one key player has emerged: hypoxia, a condition where the body is deprived of oxygen. Hypoxia is not only widespread in nature and diseases but is also closely linked to PD development. Studies indicate that hypoxia can enhance the production and clumping of alpha-synuclein (α-syn), a critical protein implicated in PD pathology. However, much remains unknown about how hypoxia contributes to α-syn accumulation and the overall progression of PD. By considering hypoxia as a common participant across various risk factors associated with PD, researchers hypothesize that this oxygen-deprivation condition may serve as a vital trigger or facilitator of α-syn pathology and PD development. This groundbreaking review offers fresh insights into the intricate web of PD’s origins and highlights the importance of investigating the role of hypoxia as a potential therapeutic target.
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, with typical motor symptoms as the main clinical manifestations. At present, there are about 10 million patients with PD in the world, and its comorbidities and complications are numerous and incurable. Therefore, it is particularly important to explore the pathogenesis of PD and find possible therapeutic targets. Because the etiology of PD is complex, involving genes, environment, and aging, finding common factors is the key to identifying intervention targets. Hypoxia is ubiquitous in the natural environment and disease states, and it is considered to be closely related to the etiology of PD. Despite research showing that hypoxia increases the expression and aggregation of alpha-synuclein (α-syn), the most important pathogenic protein, there is still a lack of systematic studies on the role of hypoxia in α-syn pathology and PD pathogenesis. Considering that hypoxia is inextricably linked with various causes of PD, hypoxia may be a co-participant in many aspects of the PD pathologic process. In this review, we describe the risk factors for PD, and we discuss the possible role of hypoxia in inducing PD pathology by these risk factors. Furthermore, we attribute the pathological changes caused by PD etiology to oxygen uptake disorder and oxygen utilization disorder, thus emphasizing the possibility of hypoxia as a critical link in initiating or promoting α-syn pathology and PD pathogenesis. Our study provides novel insight for exploring the pathogenesis and therapeutic targets of PD.
Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success of Society. With a keen interest in exploring the untapped potential of the human mind, Dr. Lowemann has dedicated his career to pushing the boundaries of human capabilities and understanding.
Armed with a Master of Science degree and a Ph.D. in his field, Dr. Lowemann has consistently been at the forefront of research and innovation, delving into ways to optimize human performance, cognition, and overall well-being. His work at the Institute revolves around a profound commitment to harnessing cutting-edge science and technology to help individuals lead more fulfilling and intelligent lives.
Dr. Lowemann’s influence extends to the educational platform BetterSmarter.me, where he shares his insights, findings, and personal development strategies with a broader audience. His ongoing mission is shaping the way we perceive and leverage the vast capacities of the human mind, offering invaluable contributions to society’s overall success and collective well-being.
